Sign in
Not yet taking people in FrancePhase 3

Landiolol to Prevent Irregular Heartbeat After Heart Surgery

Tests landiolol against placebo to prevent atrial fibrillation after heart surgery.

Key facts

Who runs it
GCS Ramsay Sante Enseignement Et Recherche
Where
Massy, Neuilly-Sur-Seine, and Saint-Denis, FranceSee the 3 sites
Registry title
Optimizing Postoperative Betablockade with Landiolol on top of oral betablocker to prevent New-Onset Atrial Fibrillation Following Cardiac Surgery in Caucasian patients
Status
Not yet recruiting
Phase
Phase 3
People taking part
400 people, planned
Started
1 Sept 2026
Expected to end
1 Sept 2028
Type of study
Interventional
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Caucasian adults aged 65 and older who are scheduled for planned heart surgery with a heart-lung machine. It tests whether landiolol, given on top of an oral beta-blocker, prevents new atrial fibrillation after surgery.

Age
65 years and older
Sex
All sexes can join.
Disease stage
Planned (elective) heart surgery using cardiopulmonary bypass, with a left ventricular ejection fraction of 50% or higher before surgery.
Earlier treatment
The record says the patients take an oral beta-blocker. It names no other treatment people must have had.

Main reasons for not taking part

  • Atrial fibrillation before surgery (paroxysmal or persistent)
  • Cannot take beta-blockers, or known allergy to landiolol
  • Severe heart conduction or rhythm problem (complete atrioventricular block or bradycardia needing external pacing)
  • Shock after heart surgery needing adrenaline or dobutamine, or vasoplegic syndrome
  • Acute respiratory distress syndrome or a moribund condition (SAPS II above 90)

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patient aged 65 years and older
  • Caucasian patient
  • Patient scheduled for elective cardiac surgery under cardiopulmonary bypass with a preoperative left ventricular ejection fraction of ≥ 50%
  • Patient affiliated with a social security scheme or equivalent
  • Free, informed and signed consent

Who cannot take part

  • History of paroxysmal or persistent atrial fibrillation prior to surgery
  • Contraindication to beta-blockers or known hypersensitivity to landiolol
  • Severe conduction or cardiac rhythm disorder (complete atrioventricular block or bradycardia requiring external pacing
  • Vasoplegic syndrome defined by a MAP < 65 mmHg despite vasopressor support with noradrenaline ≥ 0.3 μg.kg⁻¹.min⁻¹ and volume optimization
  • Acute respiratory distress syndrome defined by a PaO2/FiO2 ratio < 200
  • Patient under 65 years of age
  • Patient under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision, or hospitalized without consent
  • Patient unable to personally provide consent or legally protected adult
  • Post-cardiotomy cardiogenic shock requiring inotropic agents (adrenaline, dobutamine)
  • Moribund patient defined by a Simplified Acute Physiology Score II (SAPS II) greater than 90
  • Mental or linguistic inability to understand the study

Where in France

  • Hôpital Privé Jacques CartierMassy, FranceNot yet recruiting
  • Centre Medico Chirurgical Ambroise Pare HartmannNeuilly-Sur-Seine, FranceNot yet recruiting
  • Societe D'Exploitation Du Centre Cardiologique Du NordSaint-Denis, FranceNot yet recruiting

About the trial

What the trial wants to find out

To evaluate the effect of a preventive infusion of landiolol versus placebo on the incidence of postoperative atrial fibrillation within 7 days following cardiac surgery in Caucasian patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Optimizing Postoperative Betablockade with Landiolol on top of oral betablocker to prevent New-Onset Atrial Fibrillation Following Cardiac Surgery in Caucasian patients: A multicenter, randomized, double-blind study.
Plain-language title
Landiolol to Prevent Irregular Heartbeat After Heart SurgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 October 2026